Please assess the completion status of the following clinical trial:

Trial Title: Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 15-90 years~* Either gender~* Patients diagnosed with COVID-19 disease by RT-PCR~* Have confirmed COVID-19 symptoms and symptom onset within the past 10 days~* Capable of using a nasal spray device and perform nasal irrigation required by the study~* Willing to participate~Exclusion Criteria:~* Patient with known sensitivity to PVP-I aqueous antiseptic solution or any of its listed excipients~* Previously diagnosed thyroid disease~* Patients with chronic renal failure (stage ≥3 by estimated Glomerular Filtration rate (eGFR) Modification of Diet in Renal Disease( MDRD)~* Patients with acute renal failure (KDIGO ≥stage 2: creatinine ≥2 X baseline)~* Pregnant and lactating mother~* Current requirement for invasive or non-invasive ventilation or planned within next 6 hours.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- PVP-I 0.4% NI (Type: EXPERIMENTAL): Arm-1 will receive Povidone iodine (PVP-I) nasal irrigation (NI) at concentration of 0.4% single time
- PVP-I 0.5% NI (Type: EXPERIMENTAL): Arm-2 will receive Povidone iodine (PVP-I) nasal irrigation at concentration of 0.5% single time
- PVP-I 0.6% NI (Type: EXPERIMENTAL): Arm-3 will receive Povidone iodine (PVP-I) nasal irrigation at concentration of 0.6% single time
- PVP-I NS 0.5% NS (Type: EXPERIMENTAL): Arm-4 will receive will receive PVP-I nasal spray (NS) at concentration of 0.5% single time
- PVP-I 0.6% NS (Type: EXPERIMENTAL): Arm-5 will receive will receive PVP-I nasal spray at concentration of 0.6% single time
- DW NI (Type: PLACEBO_COMPARATOR): Arm-6 will receive distilled water through nasal irrigation
- DW NS (Type: PLACEBO_COMPARATOR): Arm-7 will receive distilled water through nasal spray

Based on this trial design, predict the completion outcome and termination type (if applicable).